Is Ibandronate + Endocrine Therapy Effective for Breast Cancer?
Is Ibandronate + Endocrine Therapy Effective for Breast Cancer?
Medical Supporter — إشعار معلوماتي
هذه المقالة ملخص لمعلومات طبية دولية وليست نصيحة طبية، ولا يمكن أن تحل محل تشخيص طبيبك المعالج أو خطة العلاج. المعلومات المعروضة مجمّعة من منشورات عامة وبيانات رسمية لكبرى المؤسسات الطبية اليابانية؛ وتختلف ملاءمة ونتائج أي علاج من مريض لآخر ويجب أن يقيّمها طبيب مؤهل لكل حالة على حدة.
Formerly certified by Japan's Ministry of Foreign Affairs Medical Visa Guarantee Agency B-66 Travel Services Arrangement Business License No. 35, Fukuoka Prefecture, Japan Japanese Medical Equipment Sales and Rental Business Management
Formerly certified by Japan's Ministry of Foreign Affairs Medical Visa Guarantee Agency B-66 Travel Services Arrangement Business License No. 35, Fukuoka Prefecture, Japan Japanese Medical Equipment Sales and Rental Business Management
Is Ibandronate + Endocrine Therapy Effective for Breast Cancer?
On April 20, 2022, Sonja B. Vliek from University Medical Center Utrecht published the results of the TEAM-IIB Phase III clinical trial on the efficacy and safety of oral Ibandronate + endocrine therapy as adjuvant treatment in estrogen receptor-positive, postmenopausal breast cancer patients in the Journal of Clinical Oncology.
The TEAM-IIB Phase III clinical trial was a multicenter, randomized, open-label trial that randomized estrogen receptor-positive, postmenopausal breast cancer patients (N = 1116) in a 1:1 ratio into two groups: Ibandronate (50mg once daily) + endocrine therapy (3-year treatment period) and endocrine therapy alone (5-year treatment period). The primary endpoint was disease-free survival.
At a median follow-up of 8.5 years, the results showed that disease-free survival showed no significant difference between the two groups. The disease-free survival rate at 3 years post-randomization was: Ibandronate + endocrine therapy group 94% versus endocrine therapy group 91%. The 5-year disease-free survival rate was: Ibandronate + endocrine therapy group 89% versus endocrine therapy group 86%.
Regarding safety, 17% (N = 97/565) of patients in the Ibandronate + endocrine therapy group discontinued treatment due to adverse events. The most common adverse effect identified was dyspepsia, occurring in Ibandronate + endocrine therapy group 16% versus endocrine therapy group 10%.
Based on TEAM-IIB results, Sonja B. Vliek and colleagues concluded that estrogen receptor-positive, postmenopausal breast cancer patients receiving oral Ibandronate + endocrine therapy as adjuvant treatment showed no significant improvement in disease-free survival and do not recommend this therapy as standard treatment.
Source: https://ascopubs.org/doi/abs/10.1200/JCO.21.00311
This website uses cookies to understand how you interact with it. By accepting, you agree to our use of cookies. Privacy Policy
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
هل تفكر في تلقّي العلاج في اليابان؟ هل تحتاج إلى معلومات ومساعدة؟
نساعدك في تنظيم المعلومات اللازمة للسفر الطبي إلى اليابان، والتواصل مع المؤسسات الطبية اليابانية، وترتيب استشارة رأي ثانٍ.الاستشارة الأولى مجانية؛ سيساعدك المستشار على توضيح الخطوات التالية.
Figure 1
Figure 2
Figure 3
Figure 4